论文部分内容阅读
目的对液基超薄技术(thinprep cytologic test,TCT)和Betheasda系统(TBS)在宫颈病变诊断中的临床应用价值进行评价。方法2005年12月~2006年5月对在体检中心就诊的635例体检者行TCT检查和TBS细胞学分类诊断,对TCT检查发现异常的患者进行阴道镜病理检查和HCⅡHPV检测。结果635例涂片中检出异常涂片66例(10.23%),其中不典型鳞状细胞(ASCUS)37例(5.83%),低度鳞状上皮内病变(LSIL)18例(2.80%),高度鳞状上皮内病变(HSIL)10例(1.57%),鳞状细胞癌(SCC)1例(0.16%)。TCT与阴道镜病理检查和HCⅡ检测的符合率是92.95%、87.00%。结论TCT技术结合TBS应用于宫颈细胞涂片配合HPV DNA检测和阴道镜活检,是筛查和诊断子宫颈癌前期病变的可靠手段。
Objective To evaluate the clinical value of thinprep cytologic test (TCT) and Betheasda system (TBS) in the diagnosis of cervical lesions. Methods From December 2005 to May 2006, TCT and TBS cytological diagnosis were performed on 635 medical patients who visited the physical examination center. Colposcopy and HCⅡHPV detection were performed on the patients with abnormal TCT examination. Results Sixty-six (10.23%) cases of abnormal smears were found in 635 smears, including 37 (5.83%) cases of atypical squamous cells (ASCUS) and 18 cases (2.80%) of low grade squamous intraepithelial lesion , 10 cases (1.57%) of high grade squamous intraepithelial lesion (HSIL) and 1 case of squamous cell carcinoma (SCC) (0.16%). The coincidence rates between TCT and colposcopy pathology and HCⅡ test were 92.95% and 87.00%. Conclusion TCT combined with TBS in cervical smears combined with HPV DNA and colposcopy biopsy is a reliable method to screen and diagnose cervical precancerous lesions.